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Abstract
Epstein-Barr Virus (EBV) is an enveloped double-stranded DNA virus of the gammaherpesvirinae sub-family that
predominantly infects humans through epithelial cells and B cells. Three EBV glycoproteins, gH, gL and gp42, form a
complex that targets EBV infection of B cells. Human leukocyte antigen (HLA) class II molecules expressed on B cells serve as
the receptor for gp42, triggering membrane fusion and virus entry. The mechanistic role of gHgL in herpesvirus entry has
been largely unresolved, but it is thought to regulate the activation of the virally-encoded gB protein, which acts as the
primary fusogen. Here we study the assembly and function of the reconstituted B cell entry complex comprised of gHgL,
gp42 and HLA class II. The structure from negative-stain electron microscopy provides a detailed snapshot of an
intermediate state in EBV entry and highlights the potential for the triggering complex to bring the two membrane bilayers
into proximity. Furthermore, gHgL interacts with a previously identified, functionally important hydrophobic pocket on
gp42, defining the overall architecture of the complex and playing a critical role in membrane fusion activation. We propose
a macroscopic model of the initiating events in EBV B cell fusion centered on the formation of the triggering complex in the
context of both viral and host membranes. This model suggests how the triggering complex may bridge the two membrane
bilayers, orienting critical regions of the N- and C- terminal ends of gHgL to promote the activation of gB and efficient
membrane fusion.
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Introduction
Epstein Barr Virus (EBV) or Human Herpesvirus 4 (HHV-4) is
a gammaherpesvirus that is ubiquitous in humans and predomi-
nantly infects host epithelial and B cells, in which it establishes
long-term latency. It is an oncogenic virus associated with a wide
array of human tumors including epithelial cell tumors such as
nasopharyngeal and gastric carcinomas, and lymphoid malignan-
cies like Hodgkin and Burkitt lymphoma. Primary infection in
children and young adults manifests itself as acute infectious
mononucleosis. Subsequent reactivations of the virus are asymp-
tomatic and managed effectively by the immune system in healthy
adults. However, immunocompromised patients suffer from severe
opportunistic disorders, such as post-transplant lymphoprolifera-
tive disease (PTLD), oral hairy leukoplakia and HIV/AIDS related
malignancies [1].
Viral membrane fusion is a requisite step for infection for all
lipid bilayer encased viruses, such as the herpesviruses, and
requires one or several virus-encoded glycoproteins that
orchestrate the merging of viral and host membranes in a
step-wise manner [2]. This overall process leads to the release
of viral capsid into the host cytoplasm initiating infection. The
entry of EBV into B cells is complex and involves at least five
different glycoproteins (EBV gp350/220, gH, gL, gp42 and gB)
[3–6]. Of these five proteins, four (gH, gL, gB and gp42) are
indispensable for membrane fusion with B cells and three (gH,
gL and gB) are required for fusion with epithelial cells [7,8].
gH, gL and gB form the core fusion machinery common to all
herpesviruses. During B cell entry, EBV gp350/220 binds to
complement receptor 2 (CR2/CD21) [9–11] concentrating
virus to the B cell surface, but this interaction does not activate
membrane fusion or virus entry. The gp42 protein forms
stable, high affinity complexes with the gHgL complex [12],
and also binds to human leukocyte antigen (HLA) class II [13]
which acts as the triggering receptor for EBV entry into B cells
[4].
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The role of gHgL in herpesvirus entry has remained unclear,
but most recently it has been suggested to act primarily as a
regulator of gB activation rather than as a direct participant in
driving membrane fusion [14]. gB is the most conserved
glycoprotein in the herpesvirus family and it belongs to the class
III viral fusion protein group, which includes the VSV G and
baculovirus gp64 fusion proteins [15]. The putative post-fusion
crystal structures of HSV and EBV gB have been solved [16,17]
and functional studies have highlighted its role as the likely fusion
protein, with two critical fusion loops that are thought to interact
directly with the host membrane [18–20]. Based on its structural
similarity with the VSV G [21] protein, herpesvirus gB is thought
to undergo a large conformational change that would drive virus-
cell membrane fusion [4].
A key role of EBV gp42 is in determining the cell tropism of the
virus. Binding of gHgL/gp42 complexes to HLA class II drives B
cell infection, but gp42 binding to gHgL inhibits EBV entry into
epithelial cells [4,8,22]. This inhibitory effect can be recapitulated
by peptides containing ,33 residues from the N-terminus of gp42
[23], which bind gHgL with similar high affinity as intact gp42.
Epithelial cell entry is thought to require a direct interaction
between gHgL and integrin receptors (avb5, avb6, and avb8 but
not avb3), distinguishing at least two distinct modes of entry
mediated by gHgL [24–26] associated with the two different
physiological target cells of the virus.
EBV gp42 is a multifunctional type II glycoprotein, with an N-
terminal domain of ,100 amino acids and a C-terminal C-type
lectin domain (CTLD). The N- and C- terminal domains engage
gHgL and HLA, respectively, to mediate B cell membrane fusion
and virus entry. We previously reported the structures of gp42 in
the presence and absence of HLA class II [27,28]. The complex
structure revealed that HLA class II binds to the gp42 CTLD
(residues 94–221) only through the HLA b-chain. The gp42
structures have shown that its N-terminal region (residues 33–93)
is extended and mostly disordered. Gp42 binds gHgL through this
flexible N terminal region with nanomolar affinity [12,23] and the
interaction has been mapped to gp42 residues 36–81 [29]. We also
identified a hydrophobic pocket (HP) located at the gp42 CTLD
canonical binding site [27,30], which is important for its ability to
trigger membrane fusion subsequent to HLA binding. The role of
the hydrophobic pocket in the gp42 CTLD has remained elusive,
but we have observed that it undergoes a small structural change
after gp42 binding to HLA [27,28], which could be important in
activating membrane fusion. Mutations within this pocket inhibit
fusion, but not binding to gHgL or HLA, highlighting its
functional importance in B cell fusion [30]. Finally, the gp42
ectodomain is cleaved in-vivo after the N-terminal transmem-
brane domain (residues 9–29) and this cleavage is required for
productive viral fusion [31].
EBV gHgL is a heterodimeric protein with a rod-shaped
structure (100 A˚ long and 30–60 A˚ wide) having four domains
arranged linearly one after the other [32]. gL is entirely contained
in domain I (D-I), which also includes the N-terminal 65 residues
of gH. Mutations that affect membrane fusion are found
throughout the EBV gHgL molecule, but studies have identified
clusters of important residues within the N- and C-terminal
domains and the D-I/D-II interface [33–36]. Structural compar-
isons with HSV-2 gHgL and PRV gH structures also reveal
conformational differences in the interdomain arrangements,
which could have functional significance [37,38]. In particular,
the D-I/D-II interdomain arrangement of EBV gHgL differs from
HSV-2 gHgL, giving rise to a large groove present only in the
EBV gHgL structure [32,37]. This D-I/D-II groove is adjacent to
a KGD motif implicated in binding integrins for mediating EBV
entry into epithelial cells. Mutation of the KGD loop also has
effects on gp42 binding and B cell fusion [39].
Here we study the assembly and structure of the biochemically
reconstituted gHgL/gp42/HLA triggering complex. We demon-
strate that the two gp42 ligands, gHgL and HLA, bind essentially
independently of each other, consistent with HLA receptor binding
inducing limited conformational changes in the viral protein
complex [28]. We determined the 29-A˚ resolution structure of the
complex by negative-stain electron microscopy (EM), demonstrat-
ing that it can adopt open and closed conformations and revealing
that the functionally important gp42 HP interacts with gHgL. We
further demonstrate that mutations located at this novel gHgL-gp42
interface disrupt membrane fusion. The overall architecture of the B
cell triggering complex suggests that it may participate in early
stages of EBV-mediated B cell entry by bringing viral and target cell
membranes into closer proximity, and by positioning key residues in
gHgL to engage the gB fusion protein.
Results
In vitro assembly of gHgL/gp42/HLA-class II triggering
complexes
We previously demonstrated that EBV gHgL and gp42 form a
tight 1:1 complex [12] and that the holo-complex with a
representative HLA molecule, HLA-DR1, can be prepared and
isolated biochemically [40]. Here we expanded these studies to
encompass another HLA isotype, HLA-DQ2, which also serves as
an EBV B cell entry receptor [4,41,42]. The individual proteins,
gHgL, gp42 and HLA-DQ2, were expressed and purified and
their interactions initially characterized by gel filtration chroma-
tography (Figure 1A). The purified proteins exhibited homoge-
nous single peak profiles consistent with their approximate
molecular weights (Table 1). Using a Superdex 200 gel filtration
column, the gp42 protein eluted at volume of ,14.5 ml
corresponding to an estimated MW of 50 kDa, the HLA-DQ2
eluted at ,12.8 ml (apparent MW ,104 kDa) and the gHgL
eluted at ,12.5 ml (apparent MW ,118 kDa) (Figure 1A).
Addition of gp42 to gHgL resulted in the quantitative formation
Author Summary
The various steps by which lipid-enveloped viruses enter
or ‘fuse’ with a host cell require the coordination of
receptor recognition, viral protein activation and large
protein conformational changes that can drive membrane
bilayer fusion. Here we report biochemical, structural and
functional experiments on the protein complex that
triggers activation of the EBV fusion protein (gB) and
entry of Epstein-Barr Virus (EBV) into B cells of the immune
system. Three viral glycoproteins (gH, gL and gp42) form a
well-defined complex with host receptor (HLA). We
isolated the complex biochemically and studied its
assembly by BLI biosensor and electron microscopy
methods. Previous crystal structures revealed a hydropho-
bic pocket (HP) on the gp42 surface that when mutated
disrupts fusion with B cells, but the critical binding ligand
remained unknown. Our experiments show that the gp42
HP interacts with gHgL and that mutations of the
predicted HP contact residues on gHgL are detrimental
for fusion. Constraints imposed by the triggering complex
architecture relative to its predicted membrane anchors
highlight a close approach and potential deformation of
both viral and host membranes affected by HLA receptor
binding as a prerequisite to viral entry.
EBV gHgL/gp42/HLA Complex Structure
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of a new, higher molecular weight peak eluting at ,11.6 ml (MW
,174 kDa), consistent with previous observations [12]. The
addition of excess HLA-DQ2 to preformed gHgL/gp42 complex
resulted in the formation of an even larger complex eluting at
10.7 ml with an estimated apparent MW of ,255 kDa, consistent
with HLA-DQ2 forming stable complexes similar to those
observed with HLA-DR1 [40] (Figure 1A). The components of
each peak were verified by SDS-PAGE (data not shown), further
demonstrating the recruitment of all proteins into the larger
,255 kDa complex peak. The elution volumes and estimated
molecular weights of the proteins and complexes are collected in
Table 1. Similar complexes could be assembled with HLA-DQ2
loaded with two different peptides in the HLA peptide-binding
groove (both endogenous and exogenous, in the form of CLIP1
and a1 gliadin peptides respectively), consistent with a minimal
impact of HLA-bound peptides on the gp42 interaction and EBV
entry. We refer to the reconstituted gHgL/gp42/HLA-DQ2
complex as the ‘‘triggering complex’’ for B cell entry.
Kinetic and thermodynamic binding constants governing
triggering complex assembly
Studies of the gp42 structure alone and in complex with HLA-
DR1 suggested the potential for conformational changes to be
induced in the gp42 hydrophobic pocket (HP) after receptor
binding [27,28]. Such conformational changes could relay the
information from HLA receptor binding to enable gHgL
activation of gB-mediated membrane fusion. We therefore
investigated quantitatively the assembly of the triggering complex,
in order to establish if the energy of HLA receptor binding might
be used to initiate conformational changes in gHgL/gp42.
The assembly of the gHgL/gp42/HLA complex can proceed
from the isolated proteins along two pathways that form a closed
thermodynamic cycle (Figure 1B). The binding of two ligands to
gp42 is not necessarily independent and there are a number of
mechanistic scenarios in which binding of gHgL and HLA to gp42
could be cooperative or competitive. If gp42 binding to gHgL is
independent of HLA binding to gp42, then the interaction of gp42
or gHgL/gp42 complexes with HLA-DQ2 would have identical
affinities (Figure 1B; top and bottom of the reaction cycle).
Similarly, if the binding of these two gp42 ligands is independent,
then gp42 binding to gHgL should be identical to the binding of
gp42/HLA-DQ2 complexes to gHgL (Figure 1B; left and right of
the reaction cycle). However, if the binding of HLA to gp42
induces, for example, conformational changes that are transmitted
to gHgL, or if gHgL and HLA molecules exhibit any other form of
coupling energetics upon binding to gp42, this would be reflected
Figure 1. Biochemical assembly of the EBV B cell triggering complex. (A) In-vitro assembly of the EBV gHgL/gp42/HLA-DQ2 triggering
complex (red, indicated by arrow) using size exclusion chromatography (S200). The triggering complex elutes at 10.7 ml (Ve, elution volume) with an
estimated apparent MW of 255 kDa (also see Table 1). This complex is formed from EBV gHgL/gp42 complex (brown) mixed with excess HLA-DQ2
(green). Excess HLA-DQ2 can be seen as a second individual peak in the red trace. EBV gHgL/gp42 complex (brown) is formed quantitatively from 1:1
molar mixture of gHgL (blue) and gp42 (purple). (B) Thermodynamic cycle linking the two pathways to the formation of the triggering complex. The
horizontal (top and bottom) reactions represent the binding of HLA to either free gp42 or to gHgL/gp42 complexes, respectively. Similarly, the
vertical (left and right) reactions represent the binding of gHgL to either gp42 or gp42/HLA complexes.
doi:10.1371/journal.ppat.1004309.g001
EBV gHgL/gp42/HLA Complex Structure
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in changes in the binding affinities of bound vs. free gp42 with
either ligand.
To examine the binding rates and affinities associated with the
formation of the gHgL/gp42/HLA complex, we used biolayer
interferometry (BLI) binding methods using a ForteBio Octet
RED96 biosensor instrument (Figure 2). In a first set of
experiments, biotinylated gHgL was immobilized on Streptavidin
(SA) biosensor tips and gp42 binding was studied by varying its
concentration over the range of 0.4–100 nM (Figure 2A). Previous
experiments using fluorescence polarization (FP) to measure the
binding between gHgL and gp42-derived peptides have estimated
the binding affinity to be on the order of 1–5 nM [23,29]. The
Octet binding data was fit globally with a 1:1 interaction model,
providing an overall affinity value (KD) of 1.4 nM for the EBV
gHgL interaction with gp42 (Figure 2A and Table 2) and a t1/2 for
dissociation of ,30 minutes. Equilibrium analysis of the BLI data
provide an independent measure of the KD of ,4 nM, consistent
with the kinetic analysis. The biosensor binding data are in overall
good agreement with the peptide FP KD estimate, suggesting that
the N-terminus of gp42 does provide the majority of the binding
energy between gp42 and gHgL.
To facilitate the measurement of gp42 binding to HLA-DQ2
in the presence and absence of gHgL, biotinylated HLA-DQ2
loaded with the CLIP1 peptide was immobilized onto SA
biosensor tips. Binding of the wt gp42 protein was investigated
over the concentration range of 2–1200 nM (Figure 2B). The
data were fit best using a 2:1 heterogeneous ligand binding
model, providing affinity values for the primary component
(KD1) of 54 nM and a binding constant of 3.2 nM for a
secondary minor component (KD2, Table 2). The 2:1 heteroge-
neous ligand model does not represent two ligands binding
simultaneously to a target protein, but is a model for 2 ligand
species binding with different binding constants. This may arise
from heterogeneity in the gp42 or the HLA proteins. Because
gp42 has a tendency to aggregate, the heterogenous ligand
kinetics could reflect the interaction of monomeric vs. aggre-
gated gp42 with HLA-DQ2. The KD1 closely follows the overall
independent KD value of 53 nM obtained upon steady state
analysis of the same data (Table 2), confirming the KD obtained
through kinetic analysis.
Complexes of gHgL/gp42 were freshly prepared and isolated
by gel filtration chromatography for comparative binding studies
with biotinylated HLA-DQ2 (Figure 2C). The concentration of
the gHgL/gp42 complexes was varied over the range between 1–
800 nM by serial dilution. Global curve fitting of the binding data
with a variety of models was attempted and a 2:1 heterogeneous
ligand model gave the best fit (Figure 2C), yielding a KD1 value of
118 nM (Table 2). The overall equilibrium affinity could be
independently estimated from the saturation of the binding curves,
providing a KD value of,120 nM for the formation of the ternary
complexes, which is in good agreement with the kinetic KD1
(Figure 2D and Table 2). Attempts to quantitatively measure
gHgL binding to preformed gp42/HLA complexes using the
biosensor were confounded by the weaker affinity and faster
dissociation rate of gp42/HLA compared to gp42/gHgL com-
plexes.
Overall, these data indicate that the binding affinity of
gHgL/gp42 with HLA-DQ2 is within 2-fold of gp42 alone,
with a free energy difference of ,0.5 kcal/mol, suggesting that
there are no major energetic interactions coupling the binding
of these two ligands to gp42. The results indicate that HLA
receptor binding does not induce major conformational
changes in the gHgL/gp42 complex that require receptor
binding energy, and that gp42 binds its two ligands essentially
independently. Previous studies have shown that the gp42
hydrophobic pocket undergoes a small change in structure
upon HLA binding [27,28], consistent with the conclusions of
these binding studies.
Electron Microscopic structure of the triggering complex
Purified gHgL/gp42/HLA-DQ2 complexes were examined by
negative-stain EM (Figure 3A). The images revealed that the
sample was composed of two major types of particles: gHgL/
Table 1. Size exclusion chromatography elution volume (Ve) and apparent MW for the gHgL, gp42 and HLA-DQ2 proteins and
complexes.
Glycoprotein or glycoprotein complex
Number of glycoprotein
components Elution Volume (Ve, ml) Apparent MW
1 (kDa)
gp42 w.t. 1 14.5 50
gp42 (C114S) 1 14.6 48
gp42 (I159C) 1 14.4 52
HLA-DQ2 (a1) 1 12.8 104
gHgL 2 12.5 118
gHgL/gp42 wt 3 11.6 174
gHgL/gp42 (I159C) 3 11.7 166
gHgL/gp42/HLA-DQ2 (a1) 4 10.7 255
gHgL/gp42/HLA-DQ2 (CLIP1) 4 10.8 245
gHgL/gp42(C114S)/HLA-DQ2 (CLIP1) 4 10.7 255
gHgL/gp42(I159C)/HLA-DQ2 (CLIP1) 4 10.7 255
gHgL/gp42(I159C)mPEG2K/HLA-DQ2 (CLIP1) 4 10.8 245
gHgL/gp42(I159C)mPEG10K/HLA-DQ2 (CLIP1) 4 9.9 360
1as calculated by the following formula based on superdex 200 calibration (linearized, semi-log plot)
log10 MW ,kDð Þ~{0:1861:Ve mlð Þz4:399, R2~0:9907
The specific peptide loaded into the HLA-DQ2 peptide binding site is indicated in parentheses (a1–a1 gliadin peptide; CLIP1 – class invariant chain derived peptide).
doi:10.1371/journal.ppat.1004309.t001
EBV gHgL/gp42/HLA Complex Structure
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gp42/HLA-DQ2 and gHgL/gp42 and only 5–10% of total
particles represented intact gHgL/gp42/HLA-DQ2. The dissoci-
ation of HLA-DQ2 might result from the low sample concentra-
tion required for the negative-stain EM corresponding to
,50 nM, which is close to the measured KD. To reconstruct the
3D structures of both gHgL complexes, homogeneous particles
were selected by image classification and the 3D reconstructions
were carried out using the random conical tilt (RCT) method [43]
implemented in the SPIDER software [44].
Class averages revealed that the gHgL/gp42 complexes adopted
different arrangements of the gp42 CTLD relative to gHgL
(Figure 3B). The CTLD appears to be able to migrate along the
length of the gHgL rod-like structure, while remaining in relatively
close proximity to the gHgL surface. These observations are
consistent with gp42 binding with high affinity through a flexible
peptide segment located within its N-terminal 86 residues, followed
by a short flexible linker separating the N-terminal domain and the
CTLD [23,27,29]. The EM observations further indicate that the
gp42 CTLD does not interact strongly with gHgL.
Analysis of the gHgL/gp42/HLA-DQ2 complexes shows that
these exist in at least two states that are approximately equally
populated (Figure 3C). Nearly 50% of the complexes adopt a
‘‘closed’’ conformation in which gHgL and HLA-DQ2 molecules
appear to be more closely aligned, whereas the other 50% adopt a
more heterogenous ‘‘open’’ state (Figure 3C). For the open state,
the two arms of the ternary complex vary in orientation with
angles of ,40u–115u relative to each other.
Representative 3D EM maps of the ternary and gHgL/gp42
complexes were obtained from particle classes with estimated
resolutions of 29 A˚ (‘‘closed’’ state), 36 A˚ (‘‘open’’ state), and 36 A˚
(gHgL/gp42 complex) (Figure 4). The successful reconstruction of
the ternary complex indicates that the gHgL/gp42/HLA-DQ2
complex adopts a relatively homogeneous architecture, particu-
larly in the closed conformational state. Although the ‘‘open’’
gHgL/gp42/HLA-DQ2 and gHgL/gp42 complexes are more
variable, representative 3D reconstructions for these complexes
were also generated (Figure 4B,C). The EM maps were used for
fitting the known component crystal structures of gHgL (PDB ID:
3PHF) and the gp42/HLA-DR1 complex (PDB ID: 1KG0). The
structures fit unambiguously in the maps (Figure 4A–C), position-
ing gp42 near to gHgL, with HLA-DQ2 projecting away from the
viral protein complex in both the open and closed conformations.
In the closed conformation, gHgL and gp42/HLA-DQ2 are in an
approximately parallel arrangement with HLA-DQ2 in proximity
to gH D-IV (Figure 4A). In the ‘‘open’’ conformation, gp42 is
rotated by about 30u, leading to gp42/HLA-DQ2 tilting towards a
more perpendicular orientation relative to gHgL (Figure 4B). The
gHgL/gp42 complex lacking HLA-DQ2 is similar to its counter-
part in the intact complex (Figure 4C).
The pseudo-atomic EM models place the gp42 hydrophobic
pocket (HP) at the interface between D-II and D-III in gHgL
(Figure 5A). The interface involves two sides of the gp42 HP,
which interact with gH residues in a loop between D-II helices (2a-
6 and 2a-7; residues K275–E282) and a D-III helix (3a-9 helix;
residues Q503–E520) (Figures 5B, 5C). Although specific contacts
cannot be conclusively identified at this resolution, gp42 residues
that have been previously shown to be important for triggering
membrane fusion are located at the interface. Linker insertion
mutants at gp42 residues 193, 206 and 210, as well as the point
mutation of F210A, reduce membrane fusion but do not affect
binding to gHgL or HLA receptor [30], and these are located close
to the gH interface (Figure 5B). The structure suggests that the
Figure 2. BioLayer interferometry (BLI) binding studies with wildtype gp42. Binding kinetics were measured with the Octet RED96
instrument (ForteBio, Pall Corporation) using wildtype (wt) gp42 protein. (A) Biotinylated EBV gHgL was immobilized on streptavidin (SA) biosensor
tips and incubated over a range of concentrations (0.4–100 nM) of soluble wt gp42. (B) Biotinylated HLA-DQ2 (CLIP1) was immobilized on
streptavidin biosensor tips and incubated over a range of concentrations (2–1200 nM) of soluble wt gp42. (C) Immobilized HLA-DQ2 (CLIP1) was
incubated with increasing concentrations of preformed gHgL/gp42 complexes (30–800 nM). Data was fit globally to different binding schemes
corresponding to a 1:1 langmuir binding isotherm (A) and a 2:1 heterogeneous ligand binding model (B and C). (D) Steady state analysis of the gHgL/
gp42 binding to HLA-DQ2 shown in C for equilibrium KD determination. Fitted kinetic and equilibrium binding constants are collected in Table 2.
doi:10.1371/journal.ppat.1004309.g002
EBV gHgL/gp42/HLA Complex Structure
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well-defined architecture of the triggering complex is at least in
part due to interactions between the gp42 CTLD and gHgL,
which is mediated through the gp42 HP. Mutations in the gp42
HP may therefore disrupt membrane fusion activity by specifically
affecting the gp42 CTLD interaction with gHgL.
The composite EM model also positions the C-termini of gH
and the HLA-class II ectodomains to one side of the triggering
complex (Figure 5A), within ,70 A˚ of each other in the closed
complex. This model suggests that the formation of the triggering
complex could affect the approach of the viral and cellular
membranes prior to membrane fusion. The gH protein trans-
membrane (TM) domain lies within ,6 residues from the
observed C-terminus of the gH ectodomain, placing the viral
membrane in close proximity to the observed structure. Superpo-
sition of HLA-DQ2 onto the HLA-DR1 in our model predicts that
,9 residues link the observed C-termini of the HLA a and b
chains to their respective TM domains and the target cell
membrane (Figure 5A). Interestingly, the gp42 ectodomain must
be cleaved from its N-terminal TM domain to be active in
membrane fusion [31], suggesting a potential geometric constraint
in this assembly. No structural information is available on the
location of the N-terminus of gp42 that is proximal to the
membrane, as this is a flexible region of ,60 amino acids (residues
33–94) that are involved in high affinity gH binding. Although the
structures incorporated into our EM model lack the gH and HLA
TM and cytoplasmic domains, there is no evidence that these
regions would affect the overall ectodomain conformations.
A mutation in the gp42 ‘‘158 loop’’ specifically disrupts
membrane fusion
Residues in a loop (the ‘158’ loop) at the junction of the gp42
HP and the HLA binding site have been implicated in mediating
conformational changes to the gp42 HP after receptor binding
[28]. Previous mutagenesis studies demonstrated that mutations in
the 158 loop could affect both HLA binding and membrane
fusion, but mutations at the tip of this loop were not tested to see if
these showed specific defects in membrane fusion but not HLA
binding [27,30]. In the EM model of the complex, residue I159,
which resides at the tip of the 158 loop, is oriented to interact with
the gH D-III helices near residues 492 and 507 (Figure 5B,C). We
mutated I159 to cysteine to test its effects on membrane fusion and
to also allow additional labeling of gp42 at this site. Since wt gp42
has an unpaired cysteine at residue 114, this was also mutated to
serine to avoid secondary labeling outside of the 159 position. Both
the C114S single mutant and C114S/I159C double mutant
(referred to as I159C) were expressed and purified to homogeneity
for membrane fusion studies. The ability of the mutants to
stimulate fusion with B cells was measured in a cell-cell fusion
assay in which CHO cells transfected with gB, gHgL and a T7
luciferase reporter construct are mixed with Daudi B cells
expressing T7 RNA polymerase. The addition of soluble gp42 to
these cells triggers fusion, which is quantified by measuring
luciferase activity [7].
First, we established that the free cysteine at residue 114 in wt
gp42 is not important for its function. The wt gp42 protein was
subjected to reduction with Tris(2-carboxyethyl) phosphine,
hydrochloride (TCEP) and alkylation with iodoacetamide (IAA)
to potentially block the free thiol and this did not affect fusion
activity (Figure 6A). The gp42 C114S mutant also showed fusion
levels comparable to wild type gp42 (Figure 6A), further indicating
that the cysteine is not a functionally important residue.
We then tested the effects of the I159C mutation in the C114S
background. The I159C mutant, treated with either TCEP alone,
to reduce the 159C thiol, or with TCEP & IAA, to reduce and
alkylate the introduced cysteine, showed a significant defect in
membrane fusion activity. The reduced and alkylated I159C
protein activity dropped to below 10% of wild type levels,
(Figure 6B). However, when the I159C mutant was only reduced
with TCEP and not alkylated, it retained some residual membrane
fusion activity, suggesting that covalent modification of the
cysteine at residue 159 by IAA was in part responsible for
reducing the mutant protein function (Figure 6B).
Figure 3. Negative-stain electron microscopic (EM) image classificaion of the EBV gHgL/gp42/HLA-DQ2 triggering complex. (A) A
representative negative-stain EM image of gHgL/gp42/HLA-DQ2 sample. (B) Representative class averages of gHgL/gp42. Shown to the side is a
schematic representation depicting the variability in the gp42 CTLD position along the length of gHgL before HLA-class II binding. (C) Representative
class averages of gHgL/gp42/HLA-DQ2 complexes in open and closed conformations in ,50:50 proportion. The particle numbers included in the
ternary complex classes are also indicated in each class average in (C).
doi:10.1371/journal.ppat.1004309.g003
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In order to demonstrate that specific modification of residue 159
was affecting gp42 function, we modified the I159C position with
larger, more easily identifiable substituents by reacting the mutant
protein with maleimide-PEG 2,000 (mPEG2K) and maleimide-
PEG10,000 (mPEG10K). Both pegylated I159C proteins could be
purified to homogeneity by gel filtration chromatography (Fig-
ure 6C). The modification could be verified by observable shifts in
apparent MW in gel filtration chromatography for both the
mPEG2K and mPEG10K modified proteins (Figure 6C) and by
SDS-PAGE for the mPEG10K modified protein. Fusion assays were
conducted with the gel filtration purified, PEG-modified I159C
mutants (Figure 6B). The pegylated I159C mutants all gave levels of
membrane fusion of 5–10%, similar to the alkylated gp42 I159C
protein, indicating that PEGylation disrupted fusion activity similarly
to the alkylated gp42 I159C protein (Figure 6B).
We investigated the binding of the I159 mutant to both gHgL
and HLA-DQ2 to rule out possible effects of the mutation on
binding to either of these gp42 ligands. Octet biosensor binding
data, obtained with both the single C114S mutant and the I159C/
C114S double mutant, show nearly identical binding of the
mutants to both gHgL and HLA-DQ2 proteins as compared to wt
gp42 (Figure 7 and Table 2). The membrane fusion experiments
demonstrate that mutation of the tip of the gp42 158 loop results
in similar defects in membrane fusion as other gp42 HP mutations.
However, in contrast to studies of previous HP mutants, here we
demonstrate quantitatively that the I159 mutation has no
significant effects on either the binding affinities or kinetics for
gHgL or HLA interactions, but nonetheless membrane fusion is
inhibited. These data further indicate that the gp42 HP
interactions with gHgL are important in fusion activation, but
Figure 4. RCT 3D reconstructions of the EBV gHgL complexes. EM structure of the intact triggering complex in the closed (A) and a
representative open (B) conformation fit with the known crystal structures of gHgL, gp42 and HLA class II. A unique solution to the fitting was
obtained either with EBV gHgL (3PHF) and gp42/HLA-DR1 complex (1KG0) (depicted here), or EBV gHgL (3PHF) and gp42 (3FD4) and HLA-DQ2
(1S9V). EBV gH and gL are shown in blue and cyan, respectively. EBV gp42 represented in hotpink, and HLA-DR1 shown in green (a-chain) and orange
(b-chain). (C) EM reconstruction and fitting of the component crystal structures of a representative conformational state of the gHgL/gp42 complex.
(D) Fourier shell correlations (FSC) of the RCT 3D reconstructions from 1,219, 604, and 657 65u-tilted particle images for the closed complex (black),
the open complex (red), and the gHgL/gp42 subcomplex (blue), respectively. The resolution of the 3D reconstruction is estimated at FSC = 0.5.
doi:10.1371/journal.ppat.1004309.g004
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do not contribute significantly to the high affinity tethering of gp42
to gHgL.
We biochemically prepared triggering complexes with the IAA-
treated gp42 I159C mutant (gHgL/I159C/HLA-DQ2) to investigate
its structure by EM, but did not observe any major differences in the
structures. The IAA-treated 159C complexes also showed an
essentially identical distribution between open (47%) and closed
(53%) complexes. We also prepared triggering complexes with
pegylated I159C mutant (gHgL/I159C-mPEG-2K/HLA-DQ2).
Stable PEGylated gHgL/gp42/HLA-DQ2 complexes could be
isolated by gel filtration chromatography (Table 1) and these resulting
complexes were examined by negative-stain EM (Figure 7E).
Although the PEGylated gp42 complexes appear to be structurally
similar to the wt triggering complex, the distribution of particles in the
open and closed conformations shifts to,78% open and 22% closed
from the ,50:50 distribution observed with wt gp42, suggesting that
disrupting the closed conformational state of the triggering complex
could be functionally important.
Mutations in gHgL at the gp42 HP interface also disrupt
membrane fusion activity
Based on the EM model, we generated mutations in gH at the
predicted interface with gp42 to test their effects on membrane
fusion (Figure 5C). Given the low resolution of the structure and
Figure 5. The pseudoatomic model of the triggering complex places the gp42 HP in contact with gH. (A) Pseudo-atomic model of the
gHgL/gp42/HLA-DQ2 complex obtained from the EM envelope fitting. The individual domains of each protein are marked and the hydrophobic
pocket (HP) in gp42 is highlighted with an arrow. The C-termini of gH and HLA chains are similarly marked and lie on one side of the complex at
,70 A˚ of each other. (B) The gp42 HP interaction site with gHgL. Two sides of the gp42 HP interact with gH between D-II and D-III, including a loop
between helices 2a-6 and 2a-7 from D-II and helix 3a-9 from D-III. Residues that have been previously mutated in the gp42 HP [30] are indicated,
H206 and T193 that had linker insertions as Ca spheres (dark blue) and F210 as sticks (dark blue) within the hydrophobic pocket (light blue Ca
spheres) as defined in [27,28], which disrupt membrane fusion activity. I159 is also shown as sticks (light blue). The gp42 HP faces away from the
observer in this orientation. The gp42 interaction with the HLA-class II b-chain (orange) brings gH and HLA into close proximity. Residue C114 which
is the only unpaired cysteine in wt gp42 is shown as sticks (light blue) (C) Close-up view of gp42 residue I159 (blue), located in the gp42 158 loop [28],
at the junction of the HLA and gH contact sites. The locations of gH mutant residues that were tested are indicated, including G276 (cyan) in the 2a-
6/2a-7 loop (D-II) and D511 and S507 in the 3a- helix 9 (D-III). The view is rotated 180u along vertical axis and then rotated 45u counter-clockwise with
the horizontal axis compared to the orientation shown in (A) and (B). Images were rendered using MacPyMol [55].
doi:10.1371/journal.ppat.1004309.g005
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the associated difficulty in accurately predicting gH-gp42 contacts,
we designed mutations that introduce an NX[S/T] consensus
motif predicted to generate novel N-linked glycosylated sites at the
interface. The mutants studied include a gH DII mutant G276N/
C278S/C335S with a nonglycosylated G276N/C278A/C335A
control (Figure 8A,B). Since C278 and C335 form a disulfide bond
in wt gH, these two residues were mutated together, to avoid
leaving a reactive free thiol at this site. Additional interface
mutants in DIII included D511N/F513S, S507N/A509S,
R488N/K490T, with corresponding controls that would not
introduce the NX[S/T] glycosylation motif (Figure 8A,C). The
DIII mutants D511N/F513S and F513S mutants were not
Figure 6. Modifications of gp42 residue I159 disrupt membrane fusion with B cells. In panels (A) and (B), CHO cells were transfected with
gB, gHgL, and a T7-Luciferase reporter and either 0.1 mg or 1.0 mg soluble purified gp42 or gp42 mutant was added 24 hours post transfection along
with T7 expressing Daudi B cells. The negative control (F12 media) was similarly transfected and mixed with Daudi cells but no soluble gp42 protein
was added. (A) The wildtype gp42 residue C114 is not important for membrane fusion activity. Treatment of wt gp42 with reducing (TCEP) and
alkylating (IAA) agents, to irreversibly block the C114 –SH group, does not affect gp42 membrane fusion activity. Mutation of C114 to serine also does
not affect membrane fusion activity, it also has no unpaired cysteines due to the mutation and hence is not treated with reducing agent or alkylating
agent. (B) Mutation and chemical modifications of gp42 residue 159 block membrane fusion activity. Fusion assay results of wt gp42, I159C (reduced
with TCEP), I159C (reduced and alkylated with IAA) and I159C site-specifically pegylated with maleimidePEG 2000 and 10000 MWavg (denoted as
mPEG2K and mPEG10K). (C) Gel filtration traces of gp42 I159C along with gp42 I159C modified with mPEG2K or mPEG10K. The shift in elution volume
(Ve) with increasing molecular weights of PEGylation is evident, allowing purification of the appropriately modified gp42 protein for fusion assays and
complex formation with gHgL and HLA for EM imaging. The peaks for the purified fraction of the gp42 mutant protein are denoted as I159C-
Untreated, I159C-mPEG2K and I159C-mPEG10K from right to left respectively. Abbreviations: TCEP is Tris(2-carboxyethyl)phosphine, hydrochloride;
IAA is Iodoacetamide and, mPEG stands for maleimide-polyethylene glycol and mPEG2K or mPEG10K denotes this chemical with a MWavg 2000 or
10,000 Da.
doi:10.1371/journal.ppat.1004309.g006
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expressed well and showed no activity in fusion (Figure 8C). The
R488N/K490T mutant exhibited a significant reduction in B cell
fusion function, but with a concomitant decrease in cell surface
expression (Figure 8C), whereas the control R488A point muta-
tion expressed similar to wildtype and had only a slight effect on B
cell fusion. The S507N/A509S and the A509S mutations both
expressed similarly to wildtype. While the A509S mutation alone
had no effect on membrane fusion, the S507N/A509S double
mutant showed a reduction of ,50% in membrane fusion with B
cells (Figure 8C), consistent with its position near the gp42 HP in
the triggering complex structure.
The introduction of a novel N-linked glycosylation site at gH
residue G276 (Figures 5C, 8B) also reduced membrane fusion
activity. The mutation of G276N/C278A/C335A does not
introduce a NX[S/T] motif for glycosylation at position 276 and
despite reduced cell surface expression, B cell fusion activity is
slightly enhanced compared to wt gH (Figure 8B). Introduction of
the glycosylation site in the G276N/C278S/C335S mutant
resulted in a strong reduction in B cell membrane fusion,
consistent with a disruption of interactions with the gp42 HP
predicted by the EM model (Figure 8B). These data indicate that
the 276 and 507 regions of gH are important in B cell membrane
fusion, although significant disruption of fusion requires the
introduction of larger perturbations than the selected point
mutations tested here. Overall, the data support the conclusion
that both sides of the predicted gp42-gHgL interface are
functionally important for B cell membrane fusion activity.
Discussion
It has been proposed that the herpesvirus gHgL protein might
play various roles in membrane fusion, potentially participating
Figure 7. Mutation of gp42 I159 does not affect binding affinity or kinetics with gHgL or HLA-DQ2. Kinetic binding experiments were
conducted similarly to Figure 2 on the OctetRED96. For panels A and B site-specifically biotinylated HLA-DQ2 (CLIP1) was immobilized on the
streptavidin (SA) biosensor tip surfaces. Binding kinetics of HLA-DQ2 (ligand) with the single mutant gp42 C114S (A) or the gp42 I159C double
mutant (B) are depicted. Global curve fitting with a 2:1 heterogeneous ligand model closely matched the experimental data. The calculated binding
curves are shown overlaid on the data from the experiment. For panels C and D, biotinylated EBV gHgL was immobilized on the streptavidin (SA)
biosensor surfaces. Binding kinetics of EBV gHgL with the single mutant gp42 C114S (C) or I159C double mutant (D) are depicted. Overlay curves
show the global fitting results using a 1:1 Langmuir binding model. Kinetic and thermodynamic binding constants are similar to binding gp42
wildtype (Figure 2 and Table 2). (E) Representative class averages of gHgL/gp42-PEG2K/HLA-DQ2 complexes. The gp42 I159C mutant was labeled
with PEG-2K maleimide and used to form complexes with gHgL and HLA-DQ2, which were by purified gel filtration chromatography. Representative
angles between the two arms of the complexes formed by gHgL and gp42/HLA are indicated as well as the number of particles included in each
class.
doi:10.1371/journal.ppat.1004309.g007
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directly in the mechanics of membrane fusion [45] or alternatively
by acting purely as a regulator of gB activation and leaving the
fusion process entirely to the fusion protein gB [4,32] The process
by which receptor binding by gHgL or gHgL/gp42 leads to gB
activation may involve gHgL conformational changes, but it has
remained largely unclear. Here we studied the assembly and
structure of the EBV B cell triggering complex, demonstrating that
there is no significant energetic coupling between the binding of
the two gp42 ligands, gHgL and HLA, suggesting that receptor
binding energy is not required to initiate large conformational
changes internally in the complex. We also determined the
negative-stain EM structure of the triggering complex, observing
that it adopts a well-defined closed state and a variable open
conformation. Docking of the crystal structures of the component
gHgL, gp42 and HLA proteins into the EM map provided a
pseudo-atomic model of the complex. In addition to indicating
that the B cell triggering complex forms well defined arrangements
of the proteins, the EM models reveal three additional unantic-
ipated observations. First, the gp42 CTLD forms direct contacts
with gHgL at the junctions of D-II/D-III (Figures 4A, 5A).
Second, the gp42 HP, a region that is critical for fusion activation,
is positioned at the interface with gHgL (Figure 5B,C). Third, the
C-terminal ends of gHgL and HLA-DQ2 are oriented to one side
of this complex, suggesting that the assembly of the triggering
Figure 8. Mutations in gH at the interface with the gp42 HP affect membrane fusion. Cell surface expression and fusion assay results with
B cells with gH mutants in the R488, S507 and D511 regions. Cell surface expression was measured using the anti-gHgL monoclonal antibody E1D1.
(A) The gH D-II and D-III sequence observed proximal to the gp42 HP from our EM model has been highlighted to show the sequence and secondary
structure indicating the mutual positions of the mutations in gH that would validate the EM model. The residue mutated to Asn (N) that gets
potentially glycosylated is shown in bold text, the NX[S/T] motif is underlined. Cystine bridge between C278–C335 is highlighted; EBV gH D-II and D-III
mutants to validate the position of residues in gH close to HP as revealed in our EM model are studied in the following panels (B) and (C); (B) gH
G276N in the background of the disulfide bond mutant C278A/C335A does not have the glycosylation motif NX[S/T] and exhibits near wildtype
fusion levels with B cells. By contrast, the G276N/C278S that introduces the glycosylation motif at 276 reduces fusion levels to lower than 40%. (C) The
R488A mutation does not have a significant effect on gHgL expression or B cell fusion, while the R488N/K90T mutation reduces expression and
membrane fusion. The D511N/F513S mutant and its control (F513S) show drastically reduced surface expression and B cell fusion. Both gH507N/
A509S and the control gH A509S are expressed near wildtype levels and the gH S507N glycosylation mutant shows a reduction in membrane fusion
activity. The mutants where the surface expression is as good as the gp42 wildtype but the fusion levels are down (below ,40% or less) are
highlighted in the rounded rectangular box. Mutants that result in potential glycosylation due to the introduced residue change are shown with a
check mark.
doi:10.1371/journal.ppat.1004309.g008
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complex may bring the viral and cellular membranes into
proximity (Figures 4A, 5A, 9). We demonstrated that mutations
of residues in both gp42 and gH at the gp42 HP-gH interface
reduce membrane fusion with B cells (Figures 6B, 8B, 8C), further
validating the EM model.
Our model of the B cell triggering complex answers several
important questions that arose from previous structural and
functional studies [4]. The gp42 HP lies above the gp42 HLA class
II binding site and is required for B cell fusion. Mutations in the
pocket abrogate fusion [30], but not HLA or gHgL binding.
Importantly we demonstrated here that mutation of gp42 residue
I159, implicated by the EM structure as interacting with gHgL,
also blocked membrane fusion, but did not alter the binding
kinetics or affinity of gp42 for gHgL or HLA-DQ2. It had
previously been postulated that gB or gHgL might interact with
the gp42 HP [28], but our EM model and functional studies clarify
that gH is the HP ligand.
We demonstrated that IAA- and PEG2K-modified gp42 159C
proteins are both defective in activating membrane fusion, but EM
images of the triggering complexes appear generally similar to the
wt complexes. Interestingly, the PEG2K modified gp42 mutant
did reveal a change in the percentage of complexes in the closed
conformation, suggesting that alterations in the stability of this
conformation could be responsible for the membrane fusion
defect. However, given that the IAA-treated I159C complexes
appear similar to wt, it may not be possible to discern small but
critically important conformational changes in the low-resolution
EM complexes that are responsible for the loss of function. It is
also possible that changes in the dynamic stability of the complexes
governed by the gp42-HP:gHgL interaction may not be evident in
the distribution of closed and open states in the IAA-treated
mutant, but this could potentially explain a reduction in fusion
efficiency.
The EM structure of the closed triggering complex reveals that
the C-termini of membrane anchored gH and HLA-DQ2 would
be positioned within 70 A˚ of each other and located to one side of
the complex at the bilayer-bilayer interface during membrane
fusion (Figure 9). C-terminal residues of gH [35] and the
membrane anchor [46] itself have been implicated as important
in fusion, although contradictory results have suggested that
soluble gHgL could either activate or inhibit membrane fusion
comparing HSV and EBV [46,47]. Studies using cryo-electron
tomography (cryo-ET) of HSV-1 fusion in two model systems,
adherent cells and synaptosomes, show distinct V/Y shaped
structures (,15 nm) bridging the viral and cellular membrane
prior to membrane fusion [48], which were interpreted as
representing gHgL and/or gB proteins. The vitreous ice frozen
structures reveal dimpling of the lipid bilayer, as well as smaller
structures near the site of membrane pinching and these V/Y
shaped structures. This study also indicated that only a few
glycoprotein complexes might be involved in organizing the viral
and cellular membranes near the site of fusion [48]. The gHgL/
gp42/HLA pseudo-atomic model that we have determined shares
this overall V/Y shape. The predicted intermembrane distances of
,10 nm for the closed gHgL/gp42/HLA complex is also similar
to the bridging structures observed in the HSV studies, suggesting
that these may represent a common structural feature formed at
initial, prefusion stages of herpesvirus entry. Our mutagenesis
studies of the gp42 HP and gH contact sites further indicate that
this bridging structure plays a critical role in promoting membrane
fusion events.
The orientation of the EBV triggering complex relative to the
viral and cellular membranes is unknown. However, comparison
to the V/Y structures observed in the HSV-1 cryo-ET study
suggests that the C-termini of the gH and HLA ectodomains might
be oriented towards the central site of closest approach of the viral
Figure 9. EBV B cell fusion model based on the gHgL/gp42/HLA (‘‘triggering complex’’) structure. (A) Model of the EBV B cell triggering
complex in the context of viral and cellular lipid bilayers, with gHgL (blue/cyan), gp42 (hot pink) and HLA class II (green/orange). Locations of the
transmembrane (TM) domains of gH and HLA- are indicated schematically with rectangles spanning the viral and cellular bilayers on one side of the
complex and a separation of,70 A˚. The C-termini of gH and HLA class II are also indicated. Although gp42 is a type II transmembrane protein, the N-
terminal TM domain must be cleaved for it to be active in fusion and the resulting location in the triggering complex of the gp42 mature N-terminus
is not known. The ,170 A˚ long complex suggests a skewed orientation of the proteins relative to the two bilayers that could bridge viral-cellular
membranes, potentially distorting and/or otherwise preparing the site for subsequent membrane fusion. This model places gL residues (Q54 and
K94) involved in gB activation on the opposite side of the gH and HLA membrane anchors. The external location of gB implied by this model may
indicate an initial peripheral activation of gB followed by its movement to a more central position to mediate membrane fusion. The gp42 HP, which
is critical for fusion activation and located at the gH D-II/D-III junction, is highlighted to show its location with respect to the triggering complex. A
potential postfusion arrangement of the triggering complex is show in the inset to the lower right. (B) Schematics of the V/Y shape of the open and
closed triggering complexes highlighting their similarity to the structures observed in cryo-ET studies of HSV-1 entry described in [48].
doi:10.1371/journal.ppat.1004309.g009
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and cellular bilayers (Figure 9). The open and closed conforma-
tions of the triggering complex observed in the EM studies suggest
that assembly of the complex, and specifically formation of the
closed conformation, could play a role in drawing the viral and
cellular membranes into closer proximity. The model of the
triggering complex positions gHgL D-I on the opposite side of the
structure from the TM domains anchored in the viral and cellular
membranes and binding HLA receptor could potentially position
D-I closer to the viral membrane surface (Figure 9). Two gL
residues (Q54 and K94) located at the tip of D-I are critical for the
specificity of gB activation [33]. This placement of D-I away from
the gH and HLA TM domains may enable the recruitment of gB
to the triggering complex through the oriented gHgL D-I site.
Once gB is activated, it could then potentially move from an
initially peripheral location to a more central region of the
virus:cell interface to directly mediate fusion between the two
membrane bilayers.
Based on these observations, we propose a model for EBV entry
into B cells, in which the triggering complex plays two potential
roles, by bringing the viral and cell membranes into closer
proximity, potentially through an open-closed conformational
transition, and by orienting gHgL to enable the activation of gB-
mediated fusion (Figure 9). The well-defined architecture of the
gHgL/gp42/HLA assembly could induce dimpling or distortions
of the viral and cellular membrane bilayers to accommodate the
complex. The short linker of gH to the viral membrane may
explain why gH D-IV residues have been shown to be important
in membrane fusion [35,36], as they could potentially play a role
in deforming the viral bilayer. The orientation of gHgL complexes
relative to the two bilayers may enable gB recruitment and
activation. Finally, the merger of the viral and host membranes
may relieve membrane distortions induced by gHgL/gp42/HLA
complexes, allowing the transmembrane domains to relocate into
the same final bilayer structure (inset, Figure 9). By contrast,
studies with epithelial cells have indicated that soluble integrin
receptor binding to gHgL may be sufficient to trigger membrane
fusion [26], suggesting potential differences in the energetics or
process for activating gB. Further comparative studies of EBV
epithelial cell triggering complexes and energetics are required to
understand how infection of these two cell types is orchestrated by
EBV fusion glycoproteins.
Materials and Methods
Expression and purification of EBV gHgL, gp42 variants
and HLA-DQ2
Detailed instructions for the expression and purification of
EBV gHgL and gp42 have been previously published [12].
Baculovirus vector expression system (BD Biosciences) was used
for making the soluble constructs of EBV gH, gL and gp42. EBV
gH residues 18–679 and gL residues 24–137 were fused to a gp64
leader sequence for secretion with the resultant addition of three
N-terminal residues AMT for gH and AMD for gL each under
the expression control of the p10 and polyhedron promoters
respectively. The gHgL protein expressed in this study had no
purification tags. Gp42 residues 33–223 were cloned into the
pBacGus-3 vector, with the gp64 signal sequence and N-terminal
6-His and S tags as previously described [12]. ESF921 media
(Expression systems) and HyQ media (Hyclone) were used for
growing Sf9 or High Five insect cells (Invitrogen) and SF+ cells
(Protein Science, Meriden, CT) respectively. Sf9 or High Five
cells were maintained at 1 million cells/ml and SF+ at 1.5 million
cells/ml every 48 hrs at 27uC incubator shaking at 135 rpm. Sf9
cells in monolayer were used for serial passage of baculovirus
stock production in T-flasks with complete TNM-FH media (BD
Biosciences). SF+ cells were used for gHgL expression and High
Five cells for gp42 expression with corresponding 2% v/v P3
(fourth generation) baculovirus stock to cells at 1.5–1.8 million/
ml at 27uC shaking at 135 rpm. Typically ,4 L of SF+ cells
expressing gHgL and 1–2 L of High Five cells expressing gp42
were processed. The expressed secreted protein was harvested
three days (72 hrs) post-infection. The secreted proteins were
isolated by affinity chromatography. E1D1 antibody coupled to
an Ultralink hydrazide resin column (Pierce, Thermo Scientific)
was used for purifying untagged gHgL, and metal-affinity resin
(Talon, Clontech or Ni-NTA resin, Qiagen) used for purifying six
His-tagged gp42 wildtype and the gp42 mutants (C114S single
and I159C double mutant). EBV gHgL was eluted with 0.1 M
glycine pH 2.5 and neutralized immediately with 1 M Tris pH 8
stock and sodium chloride to final concentration 150 mM.
Alternatively, EBV gHgL was also eluted with gentle Ag/Ab
elution buffer pH 6.6 (Pierce, Thermo Scientific). Gp42 was
eluted with 20 mM Tris, 150 mM NaCl, 300 mM Imidazole,
pH 7.4. Both gHgL and gp42 proteins were buffer exchanged to
20 mM Tris, 150 mM NaCl, pH 7.4. E1D1 hybridoma was
generously provided by L. Hutt-Fletcher (Louisiana State
University Health Sciences Center, Shreveport, LA). The
hybridoma was expanded to get soluble E1D1 protein superna-
tant from the National Cell Culture Center (NCCC, Minneap-
olis, MN). The gHgL and gp42 proteins were polished using a
Superdex 200 10/300 GL column with 20 mM Tris, 150 mM
NaCl, pH 7.4 as the final buffer.
The construct details for HLA-DQ2 have been previously
described [49]. Briefly, our present study uses the A1*0501/
B1*0201 HLA-DQ2 allele with a Fos-Jun leucine zipper pair that
replaced the transmembrane regions and stabilize the ab dimer,
along with deamidated a1 gliadin peptide (QLQPFPQPELPY) or
CLIP1 (PVSKMRMATPLLMQA) peptide covalently linked to
the N-terminal end of the b-chain by a thrombin cleavable,15-aa
linker. The C-terminal leucine zipper also could be cleaved post-
expression using 3C protease and this was done for the protein
used in EM analysis. The C-terminus of the b-chain following the
zipper includes the eight amino acid FLAG tag sequence
(DYKDDDDK) used as the purification tag, followed by a BirA
enzyme site for site-directed biotinylation. This site was
enzymatically biotinylated in vitro with Biotin-protein Ligase
(Avidity LLC, Aurora, CO) to enable kinetic studies with
streptavidin (SA) biosensor tips. Stably transfected S2 insect cells
(from Drosophila melanogaster) were used for the production of
aforementioned FLAG-tagged HLA-DQ2 protein with CLIP1
(endogenous) or a1 gliadin (exogenous) peptides. S2 cells were
maintained between 4–10 million cells/ml using complete
Schneider’s media (Invitrogen Gibco 21720) supplemented with
5% FBS (Atlanta Biologicals S12450, after heat-inactivation) and
2 mM final glutamine concentration (Gibco 25030, 200 mM
stock). Cells were amplified by gradually diluting the FBS out into
the final Baculogold Max-XP serum-free insect cell media (BD
Pharmingen 551411) with added 2 mM glutamine. Cells were
grown by shaking at 120 rpm in a 27uC incubator and induced
for HLA-DQ2 expression with final concentration of 1 mM
copper sulfate at a cell density of 6 million/ml. Media
supernatants were passed through ANTI-FLAG M2 affinity gel
resin (A2220, Sigma-Aldrich, St.Louis, MO) and eluted by
competing with free FLAG (DYKDDDDK) peptide (F3290,
Sigma-Aldrich, St.Louis, MO or RP10586-1, Genscript USA Inc.
Piscataway, NJ). The eluted HLA-DQ2 protein was concentrated
and passed through Superdex 200 (GE Healthcare Life Sciences)
as the final purification step.
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Bio-layer Interferometry (BLI) kinetics
Label-free binding interaction analyses between gp42, gp42
C114S single mutant or gp42 I159C double mutant and soluble
HLA-DQ2 (CLIP1) in the presence or absence of gHgL were
performed on the Octet RED96 (ForteBio, Pall corporation). All
interactions studies were performed with the Streptavidin (SA) dip-
and-read biosensors (ForteBio). Soluble HLA-DQ2 (CLIP1) or
EBV gHgL was biotinylated for the different assays. HLA-DQ2
was site-specifically labeled whereas EBV gHgL was labeled
randomly through primary amine linkage with biotin at 1:3 molar
ratio using the EZ-link NHS-PEG4 biotin kit (Thermo Scientific).
Comparison of acquired KD estimates to previously obtained
measurements from fluorescence polarization (FP) for gHgL
binding to gp42 [29] suggest that the random biotinylation does
not affect the binding interaction.
Kinetic and equilibrium KD analysis methodology
Kinetic analysis by global fitting of model parameters (kon, koff,
KD, kobs representing on rate, off rate, dissociation constant and
observed rate respectively of complex formation between immobi-
lized ligand and mobile analyte) across a range of analyte
concentrations simultaneously were performed using the Octet Data
Analysis software package version 7.0.1.3 (ForteBio, Pall Corpora-
tion). The 1:1 global fit was modeled by the differential equation
dR tð Þ
dt
~kobs Req{R tð Þ
 
giving values for kobs, kon from the
association phase of the sensorgram and koff from the dissociation
phase using binding data from a collective set of different analyte
concentrations fit globally. Additionally, for true 1:1 binding
kobs~kon: Analyte½ zkoff . Further, KD~koff

kon and equilibrium
response orReq~Rmax: Analyte½ = Analyte½ zKDð Þð Þ where Rmax is
the maximal response achievable by saturating the active binding site
of the immobilized ligands with the mobile analyte. The 2:1
heterogeneous ligand model with two independent binding events
to two different ligand states was modeled by
dR1 tð Þ
dt
~kobs 1 Req1{R1 tð Þ
 
and
dR2 tð Þ
dt
~kobs 2 Req2{R2 tð Þ
 
.
Additionally, kobs1~kon1: Analyte½ zkoff 1 and kobs2~kon2:
Analyte½ zkoff 2 with KD1~koff 1

kon1 and KD2~koff 2

kon2. Total
response, R=R1+R2. Equilibrium analysis was performed with the
same data sets and modeled by the equation taking the average
response at steady state orReq~Rmax: Analyte½ = Analyte½ zKDð Þð Þ
corresponding to a rectangular hyperbola.
Modification of gp42 I159C in hydrophobic pocket (HP)
with maleimide PEG 2000 and 10000
Purified gp42 I159C was treated with 4 mM TCEP pH 7.0
briefly and incubated on ice for 10 minutes to reduce to the cysteine
sulfhydrl (–SH). This treated protein was mixed in 1:100 w/w ratio
with maleimidePEG 2000 or 10000 MW (Nanocs Inc.) and
incubated at room temperature for one hour. The reaction was
stopped by adding 50 mM iodoacetamide (IAA) in PBS pH 7.4
(final) to block any remaining reduced cysteine residues. Quantitative
formation of new higher molecular weight species could be detected
for gp42 modified on Superdex 200 elution profile (Figure 6C and
Table 2) and on SDS-PAGE (data not shown). The PEGylated gp42
protein was used in complex formation with gHgL and HLA-DQ2
for EM studies and also in virus-free B cell fusion assays.
Virus-free B cell fusion assay to test gp42 HP mutants and
gH mutants
B cell fusion assays were performed as previously described [7].
Briefly, effector CHO-K1 cells were transfected with plasmids
expressing gB, gHgL and the T7 luciferase reporter gene. Twenty-
four hours post transfection, the cells were detached, counted and
mixed 1:1 with target cells expressing T7 RNA polymerase (Daudi
29 B cells), along with soluble wt gp42, gp42 C114S or gp42
I159C proteins as indicated, in a 24-well plate in Ham’s F-12
medium with 10% heat-inactivated FBS. Twenty-four hours later,
the cells were washed once with PBS and lysed with 100 mL of
passive lysis buffer (Promega). Luciferase activity was quantified by
transferring 20 mL of lysed cells to a 96-well plate and adding
100 mL of luciferase assay reagent (Promega) and luminescence
was measured on a Perkin-Elmer Victor plate reader.
Negative-stain three-dimensional EM reconstruction of
the triggering complex
For negative-stain EM, 2 mL sample was applied to a glow-
discharged grid coated with carbon film. After 30-second
incubation, the sample was blotted with filter paper and stained
with 0.8% uranyl formate. EM micrographs were recorded on a
TIETZ F415MP 16-megapixel CCD camera at 68,0276
calibrated magnification in an FEI Tecnai F20 electron micro-
scope operated at 200 kV. The micrographs were saved by 26
binning, yielding a pixel size of 4.41 A˚. The image acquisition was
performed with the assistance of Leginon automation software
[50,51].
In total, 143 pairs of random conical tilt (RCT) images were
collected for the sample of gHgL/gp42/HLA-DQ2 with the grids
tilted at two angles successively (65u and 0u) for each specimen
area of interest. 148,701 pairs of particles from tilt pairs were
picked using ApTiltPicker.py in Appion [52]. To avoid bias in
particle picking, all possible particles were picked for the following
image classification. The defocus values of 0u-tilted and 65u-tilted
micrographs were calculated by CTFFIND and CTFTILT
programs [53], respectively. The phase-flipping was performed
on particle images before classification and 3D reconstructions.
The 0u-tilted particles were classified using the Correspondence
Analysis method in SPIDER [44]. 3D RCT maps were
reconstructed from 65u-tilted particles and iteratively refined with
SPIDER by refinement of the center of 65u-tilted particles.
Representative 3D RCT maps of the intact gHgL/gp42/HLA-
DQ2 complex in the ‘‘closed’’ state, that in the ‘‘open’’ state, and
the gHgL/gp42 subcomplex were reconstructed at 29 A˚, 36 A˚,
and 36 A˚ resolution from 1,219, 604, and 657 particle images,
respectively. These maps were used for fitting by known crystal
structures of gHgL (PDB ID: 3PHF) and gp42/HLA-DR1
complex (PDB ID: 1KG0) using UCSF Chimera [54].
For the comparison of the percentage of the ‘‘closed’’ and the
‘‘open’’ states, the samples of gHgL/gp42/HLA-DQ2, IAA-
treated gHgL/I159C/HLA-DQ2, and gHgL/I159C-mPEG-2K/
HLA-DQ2 were negatively stained using the same condition. The
particles from 50 micrographs of each sample were classified using
the aforementioned method. The class averages corresponding to
the ‘‘closed’’ and the ‘‘open’’ states were isolated by visual
inspection.
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